Design and synthesis of novel organometallic complexes using boronated phenylalanine derivatives as potential anticancer agents

Abstract

Drug design and discovery studies are important because of the prevalence of diseases without available medical cures. New anticancer agents are particularly urgent because of the high mortality rate associated with cancer. A series of mononuclear gold (III) and platinum (II) complexes based on boronated phenylalanine (BPA) were designed and synthesized using 4,4’-dimethyl-2,2’-dipyridyl (L1) or 1,10-phenanthroline-5,6-dion (L2) ligands to obtain promising anticancer drug candidates. Proton nuclear magnetic resonance, infrared, mass spectrometry, and elemental analyses were utilized for chemical characterizations. Cell viability, cancer cell colony formation, endothelial tube formation, and cytoskeleton staining assays were performed using A549 lung adenocarcinoma and human umbilical vein endothelial cells (HUVECs) to investigate preliminary pharmacological activities. L1-based platinum (II) complex (BPA-L1-Pt) was the most promising complex, and has similar activity with the approved chemotherapy drug cis-platinum. Half maximal inhibitory concentration values for BPA-L1-Pt were 9.15 µM on A549s and 16.61 µM on HUVECs; the values for cis-platinum were 5.24 µM on A549s and 23.14 µM on HUVECs. Consequently, further synthesis studies should be performed to boost the cancer cell selectivity feature of BPA by varying metal and ligand types.

KEYWORDS:

• Angiogenesis
• drug design
• cell survival
• cisplatin (CAS Number: 15663-27-1)
• 4-dihydroxyborylphenylalanine (CAS Number: 76410-58-7)

Acknowledgments

The authors thank Anadolu University, Bezmialem Vakif University, and Mugla Sitki Kocman University.

Disclosure statement

No potential conflict of interest was reported by the authors.

Additional information

Funding

This study was supported by Anadolu University (Project no: 1101S019 – AÜBAP) and TUBITAK (Project no: 110S077 – SBAG-HD-560).